samedan logo
 
 
spacer
home > ict > winter 2018 > promoting patterns
PUBLICATIONS
International Clinical Trials

Promoting Patterns

The clinical trial industry is transforming, and the vision for this is simple: embrace quality and automation across the clinical trial spectrum and move closer to zero-delay trials. Why? It provides better, faster results, offers more information for sponsors, allows more innovation for CROs, and, most importantly, presents expedited outcomes for patients in need. This transformation is just beginning and requires that we challenge ourselves, our teams, partners, and clients – the entire clinical trial industry – to work smarter and eliminate preventable delays.

Data Dilemmas

Drug or device trials are fundamentally science experiments. Everyone has some familiarity with how that works from those exciting high school or college labs where one measured some Newtonian physics principle. However, unlike those, in clinical trials, the outcome is unknown, and the data are never as crisp and predictable. For the most part, the signalto- noise ratio is exceedingly small. If the data collection or the analysis processes adds more noise to the system, the signal may become undetectable. When that happens, therapies that might have helped patients in need may never be approved because the data was not handled appropriately.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Abraham Gutman founded AG Mednet in 2005 and leads the company’s mission to improve, automate, and expedite outcomes in clinical trials by ensuring quality and compliance within drug, biologic, and device trials. Abraham holds a BA in computer science from Cornell University and an MSc in computer science from Yale University, US.
spacer
Abraham Gutman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement